At a glance
- Originator Merck KGaA
- Class Heart failure therapies; Thiadiazines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias; Heart failure